{"id":"phase-3-nomac-e2-batch-a","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Breast tenderness"},{"rate":null,"effect":"Breakthrough bleeding"},{"rate":null,"effect":"Mood changes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The progestin component suppresses the luteinizing hormone (LH) surge required for ovulation, while the estrogen component stabilizes the endometrium and enhances contraceptive efficacy. Together, these hormones also increase cervical mucus viscosity, creating a barrier to sperm penetration and reducing the likelihood of fertilization.","oneSentence":"NOMAC-E2 is a combined oral contraceptive containing norethisterone acetate (progestin) and ethinyl estradiol (estrogen) that prevents pregnancy through ovulation suppression and cervical mucus thickening.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T06:41:45.315Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Contraception in women of reproductive age"}]},"trialDetails":[{"nctId":"NCT01345786","phase":"PHASE1","title":"Bioequivalence of Nomegestrol Acetate (NOMAC) and Estradiol (E2) in Commercial Versus Phase 3 Pivotal Clinical Batches of NOMAC-E2 Tablets (P06328)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2009-11","conditions":"Healthy Postmenopausal Females","enrollment":158}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[{"date":"20250821","type":"SUPPL","sponsor":"STRIDES PHARMA","applicationNumber":"ANDA078418"},{"date":"20170106","type":"SUPPL","sponsor":"STRIDES PHARMA","applicationNumber":"ANDA078418"},{"date":"20101223","type":"SUPPL","sponsor":"STRIDES PHARMA","applicationNumber":"ANDA078418"},{"date":"20250821","type":"SUPPL","sponsor":"STRIDES PHARMA","applicationNumber":"ANDA078418"},{"date":"20250821","type":"SUPPL","sponsor":"STRIDES PHARMA","applicationNumber":"ANDA078418"},{"date":"20250821","type":"SUPPL","sponsor":"STRIDES PHARMA","applicationNumber":"ANDA078418"},{"date":"20250821","type":"SUPPL","sponsor":"STRIDES PHARMA","applicationNumber":"ANDA078418"},{"date":"20250821","type":"SUPPL","sponsor":"STRIDES PHARMA","applicationNumber":"ANDA078418"},{"date":"20091014","type":"ORIG","sponsor":"STRIDES PHARMA","applicationNumber":"ANDA078418"},{"date":"20230829","type":"ORIG","sponsor":"STRIDES PHARMA INTL","applicationNumber":"ANDA212634"},{"date":"20240813","type":"SUPPL","sponsor":"STRIDES PHARMA INTL","applicationNumber":"ANDA212634"},{"date":"20240501","type":"SUPPL","sponsor":"STRIDES PHARMA INTL","applicationNumber":"ANDA212634"},{"date":"20200915","type":"ORIG","sponsor":"AVET","applicationNumber":"ANDA205360"},{"date":"20130116","type":"SUPPL","sponsor":"FOUGERA PHARMS INC","applicationNumber":"NDA021735"},{"date":"20041001","type":"ORIG","sponsor":"FOUGERA PHARMS INC","applicationNumber":"NDA021735"},{"date":"20250822","type":"SUPPL","sponsor":"FOUGERA PHARMS INC","applicationNumber":"NDA021735"},{"date":"20101230","type":"SUPPL","sponsor":"FOUGERA PHARMS INC","applicationNumber":"NDA021735"},{"date":"20190705","type":"SUPPL","sponsor":"THERATECHNOLOGIES","applicationNumber":"BLA022505"},{"date":"","type":"SUPPL","sponsor":"THERATECHNOLOGIES","applicationNumber":"BLA022505"},{"date":"20101110","type":"ORIG","sponsor":"THERATECHNOLOGIES","applicationNumber":"BLA022505"},{"date":"20150608","type":"SUPPL","sponsor":"THERATECHNOLOGIES","applicationNumber":"BLA022505"},{"date":"20141215","type":"SUPPL","sponsor":"THERATECHNOLOGIES","applicationNumber":"BLA022505"},{"date":"20111129","type":"SUPPL","sponsor":"THERATECHNOLOGIES","applicationNumber":"BLA022505"},{"date":"20111129","type":"SUPPL","sponsor":"THERATECHNOLOGIES","applicationNumber":"BLA022505"},{"date":"20190705","type":"SUPPL","sponsor":"THERATECHNOLOGIES","applicationNumber":"BLA022505"},{"date":"20190118","type":"SUPPL","sponsor":"THERATECHNOLOGIES","applicationNumber":"BLA022505"},{"date":"20150209","type":"SUPPL","sponsor":"THERATECHNOLOGIES","applicationNumber":"BLA022505"},{"date":"20130107","type":"SUPPL","sponsor":"THERATECHNOLOGIES","applicationNumber":"BLA022505"},{"date":"20240227","type":"SUPPL","sponsor":"THERATECHNOLOGIES","applicationNumber":"BLA022505"},{"date":"20250325","type":"SUPPL","sponsor":"THERATECHNOLOGIES","applicationNumber":"BLA022505"}],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SCH900121"],"phase":"marketed","status":"active","brandName":"Phase 3 NOMAC-E2 \"Batch A\"","genericName":"Phase 3 NOMAC-E2 \"Batch A\"","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NOMAC-E2 is a combined oral contraceptive containing norethisterone acetate (a progestin) and ethinyl estradiol (an estrogen) that prevents pregnancy through ovulation suppression and cervical mucus thickening. Used for Contraception in women of reproductive age.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}